CTA
ATRC icon

Carillon Tower Advisers’s AtriCure ATRC Stock Holding History

Carillon Tower Advisers’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$32.8M Buy
588,551
+226,825
+63% +$9.81M 0.2% 154
2020
Q3 		$14.4M Buy
361,726
+91,723
+34% +$3.89M 0.19% 202
2020
Q2 		$12.1M Buy
+270,003
New +$11.8M 0.09% 274

Other funds holding ATRC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Carillon Tower Advisers's ATRC Position: Q4 2020 in Review

Carillon Tower Advisers increased its AtriCure (ATRC) stake by 63% in Q4 2020, buying an estimated $9.81M and bringing the position to 588,551 shares worth $32.8M. The position accounts for 0.2% of the portfolio, ranked #154.

Carillon Tower Advisers first reported a position in ATRC in Q2 2020 and has held it in 3 quarters since. 198 funds tracked by Wall St. Rank hold ATRC as of Q4 2020.

  • Carillon Tower Advisers held 588,551 shares of AtriCure worth $32.8M as of Q4 2020.
  • Carillon Tower Advisers bought 226,825 AtriCure shares in Q4 2020, an estimated $9.81M.
  • AtriCure made up 0.2% of Carillon Tower Advisers's portfolio in Q4 2020, its #154 holding.
  • Carillon Tower Advisers first reported a position in AtriCure in Q2 2020 and has held it in 3 quarters since.
  • 198 funds tracked by Wall St. Rank held AtriCure as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.